InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Replimune Group, Inc.

REPL Clue Score21
United States Fiscal year ends March CIK 0001737953 Results filed 28 Oct 2026
Add to watchlist

What the insiders did Net selling

Individual transactions

13
Insider
Date
Role
Action
Shares
Price
Amount
Emily Luisa Hill
17 Aug 2026
Chief Financial Officer
Sell
9,256
$14.28
$132.18K
Andrew Schwendenman
10 Aug 2026
Chief Accounting Officer
Sell
7,632
$12.97
$98.99K
Konstantinos Xynos
10 Aug 2026
Chief Medical Officer
Sell
11,447
$12.97
$148.47K
Emily Luisa Hill
10 Aug 2026
Chief Financial Officer
Sell
11,448
$12.97
$148.48K
Sushil Patel
10 Aug 2026
Chief Executive Officer
Sell
39,341
$12.97
$510.25K
Emily Luisa Hill
18 May 2026
Chief Financial Officer
Sell
7,812
$5.08
$39.68K
Sushil Patel
18 May 2026
Chief Executive Officer
Sell
37,324
$5.08
$189.61K
Philip Astley-Sparke
18 May 2026
Director
Sell
17,657
$5.08
$89.70K
Christopher Sarchi
18 May 2026
Chief Commercial Officer
Sell
8,626
$5.08
$43.82K
Andrew Schwendenman
18 May 2026
Chief Accounting Officer
Sell
7,894
$5.08
$40.10K
Konstantinos Xynos
18 May 2026
Chief Medical Officer
Sell
14,023
$5.08
$71.24K
Konstantinos Xynos
17 Nov 2025
Chief Medical Officer
Sell
7,248
$9.10
$65.96K
Christopher Sarchi
17 Nov 2025
Chief Commercial Officer
Sell
5,208
$9.10
$47.39K
Show all 18 transactions →

What was left out

Form 4 filings counted 40
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 2
Sales on a Rule 10b5-1 plan 3
Sales straight out of an exercise 2
Sales at will 13
Transactions with no price 0
Shares from compensation/vesting 974,245
History held since 25 Jul 2018